The pre-clinical behavioural pharmacology of 3,4-methylenedioxymethamphetamine (MDMA).
about
MDMA and the “Ecstasy Paradigm”Neural and cardiac toxicities associated with 3,4-methylenedioxymethamphetamine (MDMA)Chronic exposure to MDMA (Ecstasy) elicits behavioral sensitization in rats but fails to induce cross-sensitization to other psychostimulants.Methylone and mCPP, two new drugs of abuse?What's in a label? Ecstasy sellers' perceptions of pill brandsLearning and memory after neonatal exposure to 3,4-methylenedioxymethamphetamine (ecstasy) in rats: interaction with exposure in adulthood.The role of monoamines in the changes in body temperature induced by 3,4-methylenedioxymethamphetamine (MDMA, ecstasy) and its derivativesPharmacological profile of novel psychoactive benzofurans.3,4-Methylenedioxymethamphetamine (MDMA) neurotoxicity in rats: a reappraisal of past and present findings.Dissociation of the neurochemical and behavioral toxicology of MDMA ('Ecstasy') by citalopram.Regulation of dorsal raphe nucleus function by serotonin autoreceptors: a behavioral perspectiveBlockade of 5-HT2 receptor selectively prevents MDMA-induced verbal memory impairmentMethylenedioxymethamphetamine (MDMA, 'Ecstasy'): a stressor on the immune system.A developmental comparison of the neurobehavioral effects of ecstasy (MDMA)Chronic tolerance to recreational MDMA (3,4-methylenedioxymethamphetamine) or Ecstasy.Effects of MDMA, MDA and MDEA on blood pressure, heart rate, locomotor activity and body temperature in the rat involve alpha-adrenoceptorsThe hidden side of drug action: brain temperature changes induced by neuroactive drugs.Behavioral effects and pharmacokinetics of (±)-3,4-methylenedioxymethamphetamine (MDMA, Ecstasy) after intragastric administration to baboonsEffects of a short-course MDMA binge on dopamine transporter binding and on levels of dopamine and its metabolites in adult male rats.Alcohol Interactions with Psychostimulants: An Overview of Animal and Human Studies.The Reinforcing and Rewarding Effects of Methylone, a Synthetic Cathinone Commonly Found in "Bath Salts"Trazodone: properties and utility in multiple disorders.A brief history of oxytocin and its role in modulating psychostimulant effects.Contribution of Impulsivity and Serotonin Receptor Neuroadaptations to the Development of an MDMA ('Ecstasy') Substance Use Disorder.The varieties of ecstatic experience: an exploration of the subjective experiences of ecstasy.Locomotor, discriminative stimulus, and place conditioning effects of MDAI in rodentsMephedrone ('bath salt') elicits conditioned place preference and dopamine-sensitive motor activation.Involvement of inferior parietal lobules in prospective memory impairment during acute MDMA (ecstasy) intoxication: an event-related fMRI study.Co-administration of THC and MDMA ('ecstasy') synergistically disrupts memory in rats.Depressive mood ratings are reduced by MDMA in female polydrug ecstasy users homozygous for the l-allele of the serotonin transporter.Rewarding effects and reinstatement of MDMA-induced CPP in adolescent mice.Progression and Persistence of Neurotoxicity Induced by MDMA in Dopaminergic Regions of the Mouse Brain and Association with Noradrenergic, GABAergic, and Serotonergic Damage.Caffeine alters the behavioural and body temperature responses to mephedrone without causing long-term neurotoxicity in rats.Active and passive MDMA ('ecstasy') intake induces differential transcriptional changes in the mouse brain.Determination of 3,4-Methylenedioxymethamphetamine (MDMA) and 3,4-Methylenedioxyamphetamine (MDA) in Urine by High Performance Liquid ChromatographyAcute MDMA and Nicotine Co-administration: Behavioral Effects and Oxidative Stress Processes in Mice
P2860
Q21558618-75AFB905-6F7C-4458-9488-ECE7741669CCQ24619949-00E34AB3-2BBE-4AC7-85E1-1015B364D49CQ25256989-9C33482D-4345-4324-A0EB-C0BAA09F746FQ28284527-BE1D57F0-3DB8-4570-98FD-DE327B626959Q28752119-418C3A03-A7E4-42E7-81E8-DF73F8D4B1BFQ33923851-7353645A-2CFE-4A71-8752-4930B3F52740Q34112933-8347B223-2D73-4BC3-A055-B196185E4DF4Q34466872-4D753157-7A51-43E0-8138-D8C722363A60Q34565712-382E8D77-6B49-4F9C-86DA-D7B2A90FAB18Q34645756-ADBDF9AB-82A3-4E15-952E-C37CAEA81A11Q35109908-11D35CD3-C514-425F-BD72-EF2BBBA95C8DQ35158204-F796AE47-FC66-4471-A81C-B1B7A14EBAD9Q35729190-78356AF2-99A5-4A9C-8B5C-B11F98C59DA8Q35851128-C2164463-27F4-4BBB-9108-5B887EC8A84AQ36020276-A780D287-F415-4743-A0C2-B5F8D6D5D265Q36357993-E2FC27FC-076F-45CA-85D8-F3F7C518B0FFQ36572459-73969217-1F77-4FC6-B0A7-931D2A5DE368Q36852604-0F9E945D-5B95-4F7C-9213-69F95FAC2E7BQ36875417-5516F114-1380-4510-B2A6-EFAEE5601EE2Q37138642-E2529338-F7EC-462A-8859-F01C31AF06FDQ37310323-B612261C-4C05-4A03-99AC-C0E8C7F516E4Q37960634-2A8648AD-33B5-412D-858D-6CEE5C7EF905Q38076658-F2EC5293-4741-4FD7-A6BB-990D94D84F43Q40157269-2CB4E11C-CC67-4A52-8384-F0BF9526BFEEQ40359394-4885ADCA-B2A1-4678-8892-AD8471641BB1Q42395888-E3BACA7E-FC5B-4641-AAE8-7852C624F957Q42409901-1F5D6584-2E87-46FE-848B-507D33D70F2BQ43776592-8826F303-4FF4-4CDB-B023-9A6684481E66Q46715759-34449D20-11E2-4FAD-BB3A-2816ED1EF924Q47551565-96C40369-D9C8-4D51-BD4C-12E897521296Q48273339-A945C337-A16C-4E39-B86E-689675351D10Q48302266-0CFB4814-F680-4FF4-8A5B-1BC288CED70AQ48697149-016F4BC0-86DD-4782-8CA8-99CD761991F9Q48876145-B10D1991-8018-4736-8FBE-5AEC64CA5F9BQ58180654-73CF70ED-D2D6-4600-9103-782268A1EAADQ58803432-FD70587E-1EF8-4A45-9582-C2A8760DE865
P2860
The pre-clinical behavioural pharmacology of 3,4-methylenedioxymethamphetamine (MDMA).
description
2003 nî lūn-bûn
@nan
2003 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
The pre-clinical behavioural pharmacology of 3,4-methylenedioxymethamphetamine (MDMA).
@ast
The pre-clinical behavioural pharmacology of 3,4-methylenedioxymethamphetamine (MDMA).
@en
type
label
The pre-clinical behavioural pharmacology of 3,4-methylenedioxymethamphetamine (MDMA).
@ast
The pre-clinical behavioural pharmacology of 3,4-methylenedioxymethamphetamine (MDMA).
@en
prefLabel
The pre-clinical behavioural pharmacology of 3,4-methylenedioxymethamphetamine (MDMA).
@ast
The pre-clinical behavioural pharmacology of 3,4-methylenedioxymethamphetamine (MDMA).
@en
P1476
The pre-clinical behavioural pharmacology of 3,4-methylenedioxymethamphetamine (MDMA)
@en
P2093
Jon C Cole
P304
P356
10.1016/S0149-7634(03)00031-9
P577
2003-05-01T00:00:00Z